These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33317473)

  • 21. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
    Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
    Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lusutrombopag: First Global Approval.
    Kim ES
    Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
    Biolato M; Vitale F; Marrone G; Miele L; Grieco A
    Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study.
    Yoshida H; Ohki T; Kanezaki M; Teratani T; Sato S; Obi S; Sato T; Akamatsu M; Uchino K; Taniguchi H
    BMC Gastroenterol; 2023 Jul; 23(1):250. PubMed ID: 37488476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study.
    Kawaratani H; Tsuji Y; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Sato S; Takaya H; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Hepatol Res; 2020 Sep; 50(9):1101-1105. PubMed ID: 32558192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between response to lusutrombopag and splenic volume.
    Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
    World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.
    Brown RS; Imawari M; Izumi N; Osaki Y; Bentley R; Ochiai T; Kano T; Peck-Radosavljevic M
    JHEP Rep; 2021 Apr; 3(2):100228. PubMed ID: 33644726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
    Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
    Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N
    Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion.
    Taki S; Ida Y; Tamai H; Maeshima S; Shimizu R; Shingaki N; Maekita T; Iguchi M; Kitano M
    Dig Dis; 2024 Apr; ():1-7. PubMed ID: 38663358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.
    Gallo P; De Vincentis A; Terracciani F; Falcomatà A; Pace Palitti V; Russello M; Vignone A; Alvaro D; Tortora R; Biolato M; Pompili M; Calvaruso V; Marzia V; Tizzani M; Caneglias A; Frigo F; Gesualdo M; Marzano A; Rosato V; Claar E; Villani R; Izzi A; Cozzolongo R; Cozzolino A; Airoldi A; Mazzarelli C; Distefano M; Iegri C; Fagiuoli S; Messina V; Ragone E; Sacco R; Cacciatore P; Masutti F; Crocé SL; Moretti A; Flagiello V; Di Pasquale G; Picardi A; Vespasiani-Gentilucci U
    J Clin Med; 2024 Jul; 13(13):. PubMed ID: 38999529
    [No Abstract]   [Full Text] [Related]  

  • 35. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study.
    Numata K; Tanaka K; Katsube T; Ochiai T; Fukuhara T; Kano T; Osaki Y; Izumi N; Imawari M
    Hepatol Res; 2020 Oct; 50(10):1141-1150. PubMed ID: 32609920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization.
    Fujita M; Abe K; Hayashi M; Okai K; Takahashi A; Ohira H
    Fukushima J Med Sci; 2017 Dec; 63(3):165-171. PubMed ID: 29142151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleeding events in lusutrombopag-treated thrombocytopenic patients.
    Giannini EG; Kano T; Ochiai T; Bentley R; Shrestha P; Afdhal N
    Eur J Clin Invest; 2021 Jun; 51(6):e13503. PubMed ID: 33523482
    [No Abstract]   [Full Text] [Related]  

  • 40. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.